Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Masonic Cancer Center, University of Minnesota |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00005987 |
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony-stimulating factors such as filgrastim and sargramostim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. Interferon alfa may interfere with the growth of cancer cells. It is not yet known which treatment regimen is more effective for multiple myeloma.
PURPOSE: Randomized phase II trial to compare the effectiveness of filgrastim with that of sargramostim plus chemotherapy, peripheral stem cell transplantation, and interferon alfa in treating patients who have multiple myeloma.
Condition | Intervention | Phase |
---|---|---|
Multiple Myeloma and Plasma Cell Neoplasm |
Drug: carmustine Drug: cyclophosphamide Drug: dexamethasone Drug: etoposide Drug: filgrastim Drug: mitoxantrone hydrochloride Drug: recombinant interferon alfa Drug: sargramostim Procedure: bone marrow ablation with stem cell support Procedure: peripheral blood stem cell transplantation Procedure: radiation therapy |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Active Control |
Official Title: | Autologous Transplantation for Multiple Myeloma: A Research Study of Multiple Myeloma Using Chemotherapy Plus Growth Factor Primed Peripheral Blood Stem Cells Followed by Autologous Transplantation and Post-Transplant Immunotherapy |
Study Start Date: | August 2000 |
OBJECTIVES:
OUTLINE: This is a randomized study. Patients are randomized to one of two treatment arms.
Patients who have received prior radiotherapy receive cyclophosphamide IV over 2 hours daily on days -6 through -3, carmustine IV over 1 hour on day -6, and etoposide IV over 4 hours every 12 hours for a total of 6 doses on days -6 through -4. Autologous PBSC are reinfused on day 0. Patients also receive GM-CSF IV over 2 hours daily and G-CSF IV over 15 minutes daily beginning on day 0 and continuing until day 28 or until blood counts recover.
All patients then receive interferon alfa SC 3 times weekly starting on day 28 and continuing until relapse or disease progression.
Patients may also undergo radiotherapy 5 days a week for 2 weeks for residual bony lesions measuring greater than 2 cm.
Patients are followed at days 28 and 100, and at 6, 9, 12, 18, 24, 30, and 36 months.
PROJECTED ACCRUAL: A total of 25-35 patients will be accrued for this study within 2-3 years.
Ages Eligible for Study: | up to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Histologically confirmed multiple myeloma
PATIENT CHARACTERISTICS:
Age:
Performance status:
Age 65-70 years:
Under 65 years:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Age 65-70 years:
Under 65 years:
Cardiovascular:
Age 65-70 years:
Under 65 years:
Pulmonary:
Age 65-70 years:
Under 65 years:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
United States, Minnesota | |
University of Minnesota Cancer Center | |
Minneapolis, Minnesota, United States, 55455 |
Study Chair: | Daniel J. Weisdorf, MD | Masonic Cancer Center, University of Minnesota |
Study ID Numbers: | CDR0000067976, UMN-MT-9216, UMN-MT-1992-16 |
Study First Received: | July 5, 2000 |
Last Updated: | July 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00005987 History of Changes |
Health Authority: | United States: Federal Government |
stage I multiple myeloma stage II multiple myeloma stage III multiple myeloma |
Anti-Inflammatory Agents Dexamethasone Interferon Type I, Recombinant Immunologic Factors Blood Protein Disorders Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Antiemetics Paraproteinemias Cyclophosphamide Hemostatic Disorders Hormones Etoposide phosphate Hemorrhagic Disorders Mitogens |
Analgesics Alkylating Agents Etoposide Dexamethasone acetate Interferon-alpha Immunoproliferative Disorders Antineoplastic Agents, Hormonal Hematologic Diseases Blood Coagulation Disorders Interferons Carmustine Vascular Diseases Glucocorticoids Immunosuppressive Agents Angiogenesis Inhibitors |
Dexamethasone Anti-Inflammatory Agents Anti-Infective Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Antiemetics Hormones Hemorrhagic Disorders Therapeutic Uses Cardiovascular Diseases Angiogenesis Modulating Agents Immunoproliferative Disorders Immune System Diseases Antineoplastic Agents, Hormonal |
Hematologic Diseases Carmustine Glucocorticoids Multiple Myeloma Neoplasms Mitoxantrone Interferon Alfa-2a Interferon Type I, Recombinant Immunologic Factors Blood Protein Disorders Antineoplastic Agents Paraproteinemias Cyclophosphamide Hemostatic Disorders Sensory System Agents |